May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Preservation of the Retinal Function Following a Single Intravitreal Injection of VIGAMOX ® Solution in Non–Human Primates
Author Affiliations & Notes
  • O. Dembinska
    Toxicology, Alcon, Fort Worth, TX
  • K. Stout
    Toxicology, Alcon, Fort Worth, TX
  • J. Griffin
    Toxicology, Alcon, Fort Worth, TX
  • D. Rodeheaver
    Toxicology, Alcon, Fort Worth, TX
  • J. Heaton
    Toxicology, Alcon, Fort Worth, TX
  • R. Rice
    Toxicology, Alcon, Fort Worth, TX
  • J. Hiddemen
    Toxicology, Alcon, Fort Worth, TX
  • Footnotes
    Commercial Relationships  O. Dembinska, Alcon Research, Ltd., E; K. Stout, Alcon Research, Ltd., E; J. Griffin, Alcon Research, Ltd., E; D. Rodeheaver, Alcon Research, Ltd., E; J. Heaton, Alcon Research, Ltd., E; R. Rice, Alcon Research Ltd., E; J. Hiddemen, Alcon Research, Ltd., E.
  • Footnotes
    Support  Alcon Research, Ltd.
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 4681. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      O. Dembinska, K. Stout, J. Griffin, D. Rodeheaver, J. Heaton, R. Rice, J. Hiddemen; Preservation of the Retinal Function Following a Single Intravitreal Injection of VIGAMOX ® Solution in Non–Human Primates . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4681.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate retinal function by electroretinography after a single intravitreal application of VIGAMOX® solution in Cynomolgus monkeys.

Methods: : In this study, either 60 µL of vehicle or 10, 20 or 60 µL of VIGAMOX® solution (50, 100 or 300 µg of moxifloxacin, respectively) was administered via a single intravitreal injection into the right eye of Cynomolgus monkeys (n=6 in each group). Retinal function was assessed with full–field electroretinograms at the baseline, 1 month and 2 months post–injection. Amplitudes and peak times of rod b–wave, mixed a–wave, mixed b–wave and cone b–wave were measured and statistically analyzed.

Results: : Eight weeks post–injection the a–waves analysis did not reveal any treatment–related significant differences in amplitudes and peak times between vehicle–injected and VIGAMOX–injected groups ([146.8±35.0 µV, 17.4±2.2 msec] vs. [183.0±27.0 µV, 15.6±0.5 msec] vs. [197.8±57.3 µV, 15.8±0.6 msec] vs. [184.7±38.5 µV, 15.2±0.7 msec]). Similarly, the analysis of rod ([163.5±53.0 µV, 72.7±4.3 msec] vs. [186.5±34.4 µV, 70.4±2.0 msec] vs. [219.3±40.8 µV, 74.3±9.0 msec] vs. [226.8±25.0 µV, 71.6±5.9 msec]), mixed ([299.5±63.1 µV, 40.5±5.7 msec] vs. [344.3±26.9 µV, 40.4±7.3 msec] vs. [363.2.8±80.7 µV, 47.4±3.2 msec] vs. [370±51.5 µV, 40.5±4.8 msec]) and cone ([122.8±23.7 µV, 30.4±0.9 msec] vs. [137.3±21.1 µV, 29.9±1.2 msec] vs. [126.7±13.8 µV, 30.8±1.1 msec] vs. [158.8±14.9 µV, 29.5±1.0 msec]) b–waves yielded no significant, treatment–related differences in amplitudes and peak times obtained from the four groups. Overall, some of the measurements for vehicle and treatment groups obtained at 8 weeks post–injection were slightly different from the values recorded at 4 weeks and at the baseline. Most probably, these results were non–treatment related consequence of the intravitreal intervention.

Conclusions: : Retinal function was similar between vehicle and VIGAMOX® solution (0.5% moxifloxacin) treated eyes of Cynomolgus monkeys as assessed by the full–field electroretinogram following a single intravitreal injection.

Keywords: electroretinography: non-clinical • antibiotics/antifungals/antiparasitics • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×